EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients

Mise à jour : Il y a 4 ans
Référence : NCT00448305

Femme Homme

Extrait

The purpose of this study is to assess the efficacy, safety and tolerability of a therapy with EndoTAG-1 + paclitaxel in combination and EndoTAG-1 alone as a rescue therapy for patients with relapsed or metastatic triple receptor negative breast cancer (a special subgroup of breast cancer).


Critère d'inclusion

  • Breast Neoplasms


Liens